TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) and Eliem Therapeutics (NASDAQ:ELYM – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.
Risk and Volatility
TransCode Therapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for TransCode Therapeutics and Eliem Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TransCode Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Eliem Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Earnings & Valuation
This table compares TransCode Therapeutics and Eliem Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TransCode Therapeutics | N/A | N/A | -$18.55 million | N/A | N/A |
| Eliem Therapeutics | N/A | N/A | -$35.12 million | ($0.53) | -4.28 |
Insider and Institutional Ownership
69.8% of Eliem Therapeutics shares are held by institutional investors. 3.6% of TransCode Therapeutics shares are held by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares TransCode Therapeutics and Eliem Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TransCode Therapeutics | N/A | -649.03% | -281.34% |
| Eliem Therapeutics | N/A | -47.03% | -45.97% |
Summary
TransCode Therapeutics beats Eliem Therapeutics on 5 of the 9 factors compared between the two stocks.
About TransCode Therapeutics
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
About Eliem Therapeutics
Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
